title: Quantitative liver parameters of HCV infection: relation to HCV genotypes, viremia and response to interferon treatment.
abstract: OBJECTIVE
  This study aimed to evaluate the relation between the number of hepatocytes positive for HCV antigens and the amount of HCV RNA in the liver and to evaluate the relationship between the above parameters and viremia levels, HCV genotype and response to interferon treatment.
  
  
  METHODS
  This was a retrospective study on 31 consecutive patients with chronic HCV-related liver disease, selected on the basis of the availability of frozen liver tissue for both liver HCV antigens detection and liver HCV RNA quantitation. HCV antigens (immunohistochemistry), liver and plasma HCV RNA (competitive RT-PCR), and HCV genotype (commercial kit) were studied.
  
  
  RESULTS
  A significant correlation (p=0.0005) was found between the amount of liver HCV RNA (log 10 copy/microg of extracted RNA) and the number of HCV-infected hepatocytes (scored from 0 to 3). These parameters were not significantly correlated with viremia levels. The highest liver HCV RNA levels and HCV antigen scores were found in patients infected with genotype 1b. Liver HCV RNA (median 541 x 10(3) vs 118 x 10(3) copy number/microg, p=0.031) and liver HCV antigens (mean score 2.3 vs 1.3, p=0.018) but not plasma HCV RNA (median 14956 x 10(3) vs 2885 [correction of 2.885] x 10(3) copy number/ml, ns) were significantly higher in patients not responding to interferon treatment compared to responders.
  
  
  CONCLUSIONS
  The tissue parameters tested in this study were significantly correlated, shared the same clinical implications and predicted short-term response to interferon treatment better than viremia levels. We suggest that these tests should be included in the study protocol of patients under evaluation for interferon treatment, basing the choice on local facilities.
authors.affiliation: Semeiotica Medica II, Azienda Ospedaliera, University of Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Ballardini
authors.forename: A
authors.initials: A
authors.lastname: Manzin
authors.forename: F
authors.initials: F
authors.lastname: Giostra
authors.forename: R
authors.initials: R
authors.lastname: Francesconi
authors.forename: P
authors.initials: P
authors.lastname: Groff
authors.forename: A
authors.initials: A
authors.lastname: Grassi
authors.forename: L
authors.initials: L
authors.lastname: Solforosi
authors.forename: S
authors.initials: S
authors.lastname: Ghetti
authors.forename: D
authors.initials: D
authors.lastname: Zauli
authors.forename: M
authors.initials: M
authors.lastname: Clementi
authors.forename: F B
authors.initials: FB
authors.lastname: Bianchi
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D018628:Gene Dosage; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics* / Q000276:immunology*; D006526:Hepatitis C / Q000235:genetics / Q000276:immunology* / Q000821:virology*; D018936:Hepatitis C Antigens / Q000032:analysis; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008099:Liver / Q000276:immunology* / Q000473:pathology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014766:Viremia
chemical_list: D000998:Antiviral Agents; D018936:Hepatitis C Antigens; D012367:RNA, Viral; D007372:Interferons